Search Result "dose-addition"
Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System
Journal: CNS & Neurological Disorders - Drug Targets
Volume: 10 Issue: 5 Year: 2011 Page: 529-535
Author(s): Bradford D. Fischer
Immunomodulating Anticancer Alkylating Drugs: Targets and Mechanisms of Activity
Journal: Current Drug Targets
Volume: 2 Issue: 2 Year: 2001 Page: 197-212
Author(s): S. Ben-Efraim
In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Journal: Current Pharmaceutical Design
Volume: 17 Issue: 2 Year: 2011 Page: 2881-2888
Author(s): Shashikant Srivastava, Tawanda Gumbo
Can Targeted Therapy be Successful without Metronomic Scheduling ?
Journal: Current Topics in Medicinal Chemistry
Volume: 12 Issue: 15 Year: 2012 Page: 1639-1642
Author(s): Nicolas Andre,Eddy Pasquier,Barton Kamen
Basal Bolus Dosing: A Clinical Experience
Journal: Current Diabetes Reviews
Volume: 1 Issue: 2 Year: 2005 Page: 215-220
Author(s): Allen B. King, Dana U. Armstrong
Peak and Trough Concentrations of Gentamicin in the Neonate: A Review of the Literature
Journal: Current Pediatric Reviews
Volume: 5 Issue: 1 Year: 2009 Page: 2-7
Author(s): Gian Maria Pacifici
Integration of Pharmacogenomics and Pharmacometrics to Support Drug Development, Regulatory and Therapeutic Decisions
Journal: Current Pharmacogenomics and Personalized Medicine
Volume: 12 Issue: 1 Year: 2014 Page: 32-42
Author(s): Mukul Minocha,Sagar Shukla,Jogarao Gobburu
C3d Enhances Immune Responses Using Low Doses of DNA Expressing the HIV-1 Envelope from Codon-Optimized Gene Sequences
Journal: Current HIV Research
Volume: 3 Issue: 2 Year: 2005 Page: 191-198
Author(s): Joseph F. Bower, Kelly L. Sanders, Ted M. Ross
Dosing Guidelines of Aminoglycosides in Neonates: A Balance Between Physiology and Feasibility
Journal: Current Pharmaceutical Design
Volume: 21 Issue: 3 Year: 2015 Page: 5699-5704
Author(s): Karel Allegaert, Veerle Cossey, John N. van den Anker
Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus
Journal: Current Cancer Drug Targets
Volume: 7 Issue: 2 Year: 2007 Page: 157-167
Author(s): Robert M. Lorence, M. Scot Roberts, James D. ONeil, William S. Groene, Jeffrey A. Miller, Stephen N Mueller, Michael K. Bamat